Gland Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1809, down 1.76% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.06% on the day, quoting at 25392.05. The Sensex is at 83172.83, up 0.27%.Gland Pharma Ltd has lost around 6.26% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has increased around 2.13% in last one month and is currently quoting at 23025.2, down 0.76% on the day. The volume in the stock stood at 77964 shares today, compared to the daily average of 3.85 lakh shares in last one month.The PE of the stock is 28.14 based on TTM earnings ending June 24.Powered by Capital Market - Live

Gland Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 1936.35, up 1.59% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.02% on the day, quoting at 24856.05. The Sensex is at 81295.07, up 0.14%. Gland Pharma Ltd has slipped around 4.99% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has slipped around 3.48% in last one month and is currently quoting at 23043.4, down 0.28% on the day. The volume in the stock stood at 3.79 lakh shares today, compared to the daily average of 4.18 lakh shares in last one month.The PE of the stock is 29.1 based on TTM earnings ending June 24.Powered by Capital Market - Live

Revenue from operations jumped 15.97% YoY to Rs 1,401.70 crore in Q1 FY25. Profit before tax (PBT) stood at Rs 218.24 crore, down 16.47% as compared with Rs 261.26 crore in Q1 FY24. EBITDA fell to Rs 265.4 crore during the quarter as compared with Rs 298.2 crore in Q1 FY23, registering de-growth of 11%. EBITDA margin reduced from 25% to 19% during the quarter. Revenue from US market stood at Rs 762.8 crore (up 27% YoY), revenue Europe was at Rs 256.6 crore (up 15% YoY), Canada, Australia and New Zealand stood at Rs 44.7 crore (up 72% YoY) while revenue from India was at Rs 52.7 crore (down 19% YoY) and Rest of the world was at Rs 284.9 crore (down 3% YoY) during the period under review. Total capex incurred during the quarter was Rs 63.7 crore. R&D expenses stood at Rs 48.9 crore in Q1 FY25, (5% of revenue). Cenexi's gross profit jumped 24% to Rs 302.6 crore during the quarter as comapred with Rs 243.6 crore in Q1 FY24. Revenue from operations increased 21% YoY to Rs 388.3 crore during the quarter. On outlook front, the company said that In Q2 FY25 Lower activity levels are expected due to the European holiday season and planned summer maintenance shutdowns. The Fontenay plant will have an extended 3-week shutdown for new ampoule line installation. It expects positive EBITDA for Q4 of this fiscal year and a positive EBITDA for the next fiscal year, driven by increased revenue exceeding the '200 million threshold. Srinivas Sadu, executive chairman and CEO of Gland Pharma, said, 'We reached Rs 1,401.7 crore in total revenue, a 16% increase from Q1FY24. This growth aligns with our projections and is primarily driven by the US market, which saw a 27% revenue increase led by existing and certain new products. Our base business EBITDA margins were at 29%, and consolidated EBITDA margins for the quarter were 19%, mainly affected by Cenexi. We're confident in our ability to meet our fiscal year goals and are excited about the growing opportunities and even stronger results expected in the coming quarters.' Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.Powered by Capital Market - Live

Net profit of Gland Pharma declined 25.94% to Rs 143.76 crore in the quarter ended June 2024 as against Rs 194.10 crore during the previous quarter ended June 2023. Sales rose 15.97% to Rs 1401.71 crore in the quarter ended June 2024 as against Rs 1208.69 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1401.711208.69 16 OPM %18.8624.32 - PBDT310.21326.58 -5 PBT218.25261.27 -16 NP143.76194.10 -26 Powered by Capital Market - Live

The said inspection was conducted between 25 July 2024 and 02 August 2024. The said inspection was concluded with three Form 483 Observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the US FDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity,' the company said in a statement. Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India. The pharma company reported a consolidated net profit of Rs 192.42 crore in Q4 FY24, steeply higher than Rs 78.68 crore posted in Q4 FY23. Revenue from operations soared 95.85% to Rs 1,537.5 crore during the quarter as against Rs 785.01 crore recorded in Q4 FY23. The scrip fell 2.52% to currently trade at Rs 2074.10 on the BSE. Powered by Capital Market - Live